Breaking News

Teva Pharmaceuticals USA, Inc., v. GlaxoSmithKline, LLC

Pending petition
Docket No. Op. Below Argument Opinion Vote Author Term
22-37 Fed. Cir. TBD TBD TBD TBD TBD

Issue: Whether a generic drug manufacturer's FDA-approved label that carves out all of the language the brand manufacturer has identified as covering its patented uses can be held liable on a theory that its label still intentionally encourages infringement of those carved-out uses.

SCOTUSblog Coverage

DateProceedings and Orders (key to color coding)
Apr 29 2022Application (21A677) to extend the time to file a petition for a writ of certiorari from May 12, 2022 to July 11, 2022, submitted to The Chief Justice.
May 03 2022Application (21A677) granted by The Chief Justice extending the time to file until July 11, 2022.
Jul 11 2022Petition for a writ of certiorari filed. (Response due August 12, 2022)
Jul 25 2022Motion to extend the time to file a response from August 12, 2022 to September 12, 2022, submitted to The Clerk.
Jul 26 2022Motion to extend the time to file a response is granted and the time is extended to and including September 12, 2022.
Aug 10 2022Brief amici curiae of 42 Professors of Law, Economics, Business, and Medicine filed.
Aug 12 2022Brief amicus curiae of Alvotech filed.
Aug 12 2022Brief amicus curiae of Mylan Pharmaceuticals Inc. filed.
Aug 12 2022Brief amicus curiae of Association for Accessible Medicines filed.